<DOC>
	<DOCNO>NCT01097018</DOCNO>
	<brief_summary>The trial compare overall survival perifosine plus capecitabine placebo plus capecitabine patient refractory advanced colorectal cancer .</brief_summary>
	<brief_title>Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine Patients With Refractory Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients must fail available therapy treatment advance colorectal cancer , include fluoropyrimidine , irinotecan , oxaliplatin , bevacizumab Kras wildtype ( WT ) patient , antiEGFR antibody ( cetuximab panitumumab ) contain therapy . For oxaliplatinbased therapy , failure therapy also include patient oxaliplatin discontinued secondary toxicity . No prior exposure capecitabine metastatic colorectal cancer setting , except limitedcourse radiosensitizing capecitabine Patients must least one measurable lesion RECIST criterion Patients know dipyrimidine dehydrogenase ( DPD ) deficiency prior severe reaction 5FU</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>